[Novel hormone treatment for advanced prostate cancer].
Neuartige Hormontherapien beim fortgeschrittenen Prostatakarzinom.
Androgen deprivation therapy
Androgen receptor inhibitors
Prostatic neoplasms
Systemic treatment
Targeted therapies
Journal
Urologie (Heidelberg, Germany)
ISSN: 2731-7072
Titre abrégé: Urologie
Pays: Germany
ID NLM: 9918384886606676
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
accepted:
13
03
2023
medline:
8
5
2023
pubmed:
28
4
2023
entrez:
28
4
2023
Statut:
ppublish
Résumé
The systemic treatment of advanced prostate cancer (PCa) has undergone an absolute revolution in the past decade. Numerous new substances have been approved for all stages of advanced disease and treatment has been increasingly intensified. The focus continues to be on substances with an effect on the androgen receptor axis. In this review, approved treatment options for metastatic hormone-sensitive PCa (mHSPC), non-metastatic castration-refractory PCa (nmCRPC) and metastatic castration-refractory PCa (mCRPC) are summarized. A special focus is on novel hormone therapeutic agents. Based on recent trial data, potential triple combinations for mHSPC as well as treatment sequence options and novel targeted agents for mCRPC are also highlighted. Die Systemtherapie des fortgeschrittenen Prostatakarzinoms (PCa) hat im vergangenen Jahrzehnt eine regelrechte Revolution erlebt. In allen Krankheitsstadien kam es sowohl zur Zulassung neuer Substanzen wie auch zu einer zunehmenden Intensivierung der Therapie. Hierbei stehen weiterhin und insbesondere Substanzen mit einer Wirkung auf die Androgenrezeptorachse im Mittelpunkt. In der vorliegenden Übersichtsarbeit werden zugelassene Therapieoptionen für das metastasierte hormonsensitive PCa (mHSPC), das nichtmetastasierte (nmCRPC) sowie das metastasierte kastrationsrefraktäre PCa (mCRPC) zusammengefasst. Ein besonderer Fokus liegt auf den neuartigen Hormontherapeutika. Anhand aktueller Studiendaten werden zudem mögliche Dreifachkombinationen beim mHSPC sowie Therapiesequenzoptionen und neue zielgerichtete Substanzen beim mCRPC vorgestellt.
Autres résumés
Type: Publisher
(ger)
Die Systemtherapie des fortgeschrittenen Prostatakarzinoms (PCa) hat im vergangenen Jahrzehnt eine regelrechte Revolution erlebt. In allen Krankheitsstadien kam es sowohl zur Zulassung neuer Substanzen wie auch zu einer zunehmenden Intensivierung der Therapie. Hierbei stehen weiterhin und insbesondere Substanzen mit einer Wirkung auf die Androgenrezeptorachse im Mittelpunkt. In der vorliegenden Übersichtsarbeit werden zugelassene Therapieoptionen für das metastasierte hormonsensitive PCa (mHSPC), das nichtmetastasierte (nmCRPC) sowie das metastasierte kastrationsrefraktäre PCa (mCRPC) zusammengefasst. Ein besonderer Fokus liegt auf den neuartigen Hormontherapeutika. Anhand aktueller Studiendaten werden zudem mögliche Dreifachkombinationen beim mHSPC sowie Therapiesequenzoptionen und neue zielgerichtete Substanzen beim mCRPC vorgestellt.
Identifiants
pubmed: 37115299
doi: 10.1007/s00120-023-02081-w
pii: 10.1007/s00120-023-02081-w
doi:
Substances chimiques
Antineoplastic Agents
0
Androgen Antagonists
0
Hormones
0
Types de publication
Review
English Abstract
Journal Article
Langues
ger
Sous-ensembles de citation
IM
Pagination
529-539Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.
Références
Huggins C, Hodges CV (1972) Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 22(4):232–240
doi: 10.3322/canjclin.22.4.232
pubmed: 4625049
Fachinformation Zytiga. https://www.ema.europa.eu/en/documents/product-information/zytiga-epar-product-information_de.pdf . Zugriffsdatum: 23.04.2023
Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY et al (2019) Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 20(5):686–700
doi: 10.1016/S1470-2045(19)30082-8
pubmed: 30987939
Fachinformation Erleada. https://www.ema.europa.eu/en/documents/product-information/erleada-epar-product-information_de.pdf . Zugriffsdatum: 23.04.2023
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S et al (2020) Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med 383(11):1040–1049
doi: 10.1056/NEJMoa2001342
pubmed: 32905676
Halabi S, Jiang S, Terasawa E, Garcia-Horton V, Ayyagari R, Waldeck AR et al (2021) Indirect comparison of darolutamide versus apalutamide and enzalutamide for nonmetastatic castration-resistant prostate cancer. J Urol 206(2):298–307
doi: 10.1097/JU.0000000000001767
pubmed: 33818140
Fachinformation Nubequa. https://www.ema.europa.eu/en/documents/product-information/nubeqa-epar-product-information_de.pdf . Zugriffsdatum: 23.04.2023
Fachinformation Xtandi. https://www.ema.europa.eu/en/documents/product-information/xtandi-epar-product-information_de.pdf . Zugriffsdatum: 23.04.2023
Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY et al (2017) Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377(4):352–360
doi: 10.1056/NEJMoa1704174
pubmed: 28578607
Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373(8):737–746
doi: 10.1056/NEJMoa1503747
pubmed: 26244877
pmcid: 4562797
Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED et al (2022) Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 386(12):1132–1142
doi: 10.1056/NEJMoa2119115
pubmed: 35179323
pmcid: 9844551
Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Flechon A et al (2022) Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design. Lancet 399(10336):1695–1707
doi: 10.1016/S0140-6736(22)00367-1
pubmed: 35405085
Thomas C, Baunacke M, Erb HHH, Fussel S, Erdmann K, Putz J et al (2022) Systemic triple therapy in metastatic hormone-sensitive prostate cancer (mHSPC): ready for prime time or still to be explored? Cancers (Basel) 14(1):8
doi: 10.3390/cancers14010008
Chi KN, Protheroe A, Rodriguez-Antolin A, Facchini G, Suttman H, Matsubara N et al (2018) Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncol 19(2):194–206
doi: 10.1016/S1470-2045(17)30911-7
pubmed: 29326030
James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP et al (2017) Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 377(4):338–351
doi: 10.1056/NEJMoa1702900
pubmed: 28578639
pmcid: 5533216
Hoyle AP, Ali A, James ND, Cook A, Parker CC, de Bono JS et al (2019) Abiraterone in “high-” and “low-risk” metastatic hormone-sensitive prostate cancer. Eur Urol 76(6):719–728
doi: 10.1016/j.eururo.2019.08.006
pubmed: 31447077
Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R et al (2019) Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 381(1):13–24
doi: 10.1056/NEJMoa1903307
pubmed: 31150574
Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S et al (2019) Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 381(2):121–131
doi: 10.1056/NEJMoa1903835
pubmed: 31157964
Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A et al (2019) ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol 37(32):2974–2986
doi: 10.1200/JCO.19.00799
pubmed: 31329516
pmcid: 6839905
Kombination mit Enza. https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/final-overall-survival-os-analysis-from-arches-a-phase-iii-randomized-double-blind-placebo-pbo-controlled-study-of-enzalutamide-enza-an . Zugriffsdatum: 23.04.2023
Fendler WP, Weber M, Iravani A, Hofman MS, Calais J, Czernin J et al (2019) Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer. Clin Cancer Res 25(24):7448–7454
doi: 10.1158/1078-0432.CCR-19-1050
pubmed: 31511295
Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN et al (2018) Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 378(15):1408–1418
doi: 10.1056/NEJMoa1715546
pubmed: 29420164
https://www.urotoday.com/conference-highlights/asco-2020/asco-2020-prostate-cancer/121848-asco-2020-final-survival-results-from-spartan-a-phase-iii-study-of-apalutamide-versus-placebo-in-patients-with-nonmetastatic-castration-resistant-prostate-cancer.html . Zugriffsdatum: 23.04.2023
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S et al (2019) Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 380(13):1235–1246
doi: 10.1056/NEJMoa1815671
pubmed: 30763142
Fizazi K, Shore ND, Tammela T, Ulys A, Vjaters E, Polyakov S et al (2020) Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC). J Clin Oncol 38(15):5514
doi: 10.1200/JCO.2020.38.15_suppl.5514
Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U et al (2018) Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med 378(26):2465–2474
doi: 10.1056/NEJMoa1800536
pubmed: 29949494
pmcid: 8288034
Tombal B, Saad F, Penson D, Hussain M, Sternberg CN, Morlock R et al (2019) Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 20(4):556–569
doi: 10.1016/S1470-2045(18)30898-2
pubmed: 30770294
Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF et al (2020) Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 382(23):2197–2206
doi: 10.1056/NEJMoa2003892
pubmed: 32469184
Hird AE, Magee DE, Bhindi B, Ye XY, Chandrasekar T, Goldberg H et al (2020) A systematic review and network meta-analysis of novel androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer. Clin Genitourin Cancer 18(5):343–350
doi: 10.1016/j.clgc.2020.02.005
pubmed: 32278840
Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ et al (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13(10):983–992
doi: 10.1016/S1470-2045(12)70379-0
pubmed: 22995653
Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS et al (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371(5):424–433
doi: 10.1056/NEJMoa1405095
pubmed: 24881730
pmcid: 4418931
Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN et al (2015) Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16(2):152–160
doi: 10.1016/S1470-2045(14)71205-7
pubmed: 25601341
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367(13):1187–1197
doi: 10.1056/NEJMoa1207506
pubmed: 22894553
Khalaf DJ, Annala M, Taavitsainen S, Finch DL, Oja C, Vergidis J et al (2019) Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncol 20(12):1730–1739
doi: 10.1016/S1470-2045(19)30688-6
pubmed: 31727538
Loriot Y, Bianchini D, Ileana E, Sandhu S, Patrikidou A, Pezaro C et al (2013) Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol 24(7):1807–1812
doi: 10.1093/annonc/mdt136
pubmed: 23576708
de Wit R, de Bono J, Sternberg CN, Fizazi K, Tombal B, Wulfing C et al (2019) Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med 381(26):2506–2518
doi: 10.1056/NEJMoa1911206
pubmed: 31566937
Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K et al (2021) Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 385(12):1091–1103
doi: 10.1056/NEJMoa2107322
pubmed: 34161051
pmcid: 8446332
Ohlmann CH, Jaschke M, Jaehnig P, Krege S, Gschwend J, Rexer H et al (2022) LHRH sparing therapy in patients with chemotherapy-naive, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial. Prostate Cancer Prostatic Dis 25(4):778–784
doi: 10.1038/s41391-022-00533-6
pubmed: 35430584
pmcid: 9705242
de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S et al (2020) Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med 382(22):2091–2102
doi: 10.1056/NEJMoa1911440
pubmed: 32343890
Li L, Karanika S, Yang G, Wang J, Park S, Broom BM et al (2017) Androgen receptor inhibitor-induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Sci Signal 10(480):eaam7479. https://doi.org/10.1126/scisignal.aam7479
doi: 10.1126/scisignal.aam7479
pubmed: 28536297
pmcid: 5855082
de Bono J, Mateo J, Fizazi K et al (2020) Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med 382(22):2091–2102. https://doi.org/10.1056/NEJMoa1911440
Chi KN, Rathkopf DE, Smith MR, Efstathiou E, Attard G, Olmos D et al (2022) Phase 3 MAGNITUDE study: first results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations. J Clin Oncol 40(6):12
doi: 10.1200/JCO.2022.40.6_suppl.012
Merseburger AS, Attard G, Astrom L, Matveev VB, Bracarda S, Esen A et al (2022) Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study. Lancet Oncol 23(11):1398–1408
doi: 10.1016/S1470-2045(22)00560-5
pubmed: 36265504
ODM-208. https://oncologypro.esmo.org/meeting-resources/esmo-congress/preliminary-phase-ii-results-of-the-cypides-study-of-odm-208-in-metastatic-castration-resistant-prostate-mcrpc-cancer-patients . Zugriffsdatum: 23.04.2023